{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:10:46Z","timestamp":1790125846550,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"39","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.vaccine.2012.07.001","type":"journal-article","created":{"date-parts":[[2012,7,15]],"date-time":"2012-07-15T00:17:34Z","timestamp":1342311454000},"page":"5755-5760","source":"Crossref","is-referenced-by-count":40,"title":["Acceptability of human papillomavirus vaccination and sexual experience prior to disclosure to health care providers among men who have sex with men in Vancouver, Canada: Implications for targeted vaccination programs"],"prefix":"10.1016","volume":"30","author":[{"given":"Claudia","family":"Rank","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Ogilvie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri C.","family":"Jayaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rick","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Trussler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Hogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reka","family":"Gustafson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.07.001_bib0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1155\/2007\/159137","article-title":"HPV infection in men","volume":"23","author":"Palefsky","year":"2007","journal-title":"Dis Markers"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0010","series-title":"IARC monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses","author":"International Agency for Research on Cancer (IARC)","year":"2007"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0015","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/QAD.0b013e3283023f78","article-title":"Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy","volume":"22","author":"Piketty","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0020","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/jnci\/92.18.1500","article-title":"Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome","volume":"92","author":"Frisch","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.20364","article-title":"Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973\u20132000","volume":"101","author":"Johnson","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0035","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJMoa1010971","article-title":"HPV vaccine against anal HPV infection and anal intraepithelial neoplasia","volume":"365","author":"Palefsky","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0040","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S1473-3099(10)70219-X","article-title":"Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis","volume":"10","author":"Kim","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0045","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1136\/sti.2008.032581","article-title":"What men who have sex with men think about the human papillomavirus vaccine","volume":"85","author":"Simatherai","year":"2009","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0050","unstructured":"Public Health Agency of Canada. HIV\/AIDS: M-Track Survey. Available at: http:\/\/www.phac-aspc.gc.ca\/aids-sida\/about\/mtrack-eng.php."},{"key":"10.1016\/j.vaccine.2012.07.001_bib0055","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/01.OLQ.0000078823.05041.9E","article-title":"Viral sexually transmitted disease vaccine acceptability among college students","volume":"30","author":"Boehner","year":"2003","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3200\/JACH.57.1.23-32","article-title":"Intent to receive and HPV vaccine among university men and women and implications for vaccine administration","volume":"57","author":"Jones","year":"2008","journal-title":"J Am Coll Health"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0065","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.puhe.2008.02.010","article-title":"Young adults and acceptance of the human papillomavirus vaccine","volume":"122","author":"Lenselink","year":"2008","journal-title":"Public Health"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0070","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/OLQ.0b013e31818606fc","article-title":"Human papillomavirus vaccine acceptability among young adult men","volume":"36","author":"Gerend","year":"2009","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0075","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3122\/jabfm.2009.01.080008","article-title":"Variables associated with human papillomavirus (HPV) acceptance by men","volume":"22","author":"Ferris","year":"2009","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/OLQ.0b013e3181bf542c","article-title":"Acceptability of HPV vaccine among a national sample of gay and bisexual men","volume":"37","author":"Reiter","year":"2010","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0085","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6,11,16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0090","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/1055-9965.EPI-10-1160","article-title":"Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV infection in men study (HIM study)","volume":"20","author":"Lu","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0110","unstructured":"Gilbert M, Gustafson P, Xia M, Michelow W, Robert W, Trussler T, et al. Impact of statistical adjustment for frequency of venue attendance in the Vancouver site of the M-Track HIV surveillance system. Presented at: 21st Annual Canadian Conference on HIV\/AIDS Research. 2012."},{"key":"10.1016\/j.vaccine.2012.07.001_bib0100","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.07.001_bib0105","unstructured":"Media Advisory ACIP recommends all 11\u201312 year-old males get vaccinated against HPV (Recommendations subject to approval by CDC). Available at: http:\/\/www.cdc.gov\/media\/releases\/2011\/a1025_ACIP_HPV_Vote.html; [accessed 18.11.11]."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12009899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12009899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T23:26:51Z","timestamp":1542842811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12009899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":21,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0264410X12009899"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.07.001","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}